EP1192174A4 - Antagonisten von bmp- und tgf-beta signalwegen - Google Patents

Antagonisten von bmp- und tgf-beta signalwegen

Info

Publication number
EP1192174A4
EP1192174A4 EP00941398A EP00941398A EP1192174A4 EP 1192174 A4 EP1192174 A4 EP 1192174A4 EP 00941398 A EP00941398 A EP 00941398A EP 00941398 A EP00941398 A EP 00941398A EP 1192174 A4 EP1192174 A4 EP 1192174A4
Authority
EP
European Patent Office
Prior art keywords
smurf1
bmp
tgfβ
signalling
smurf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00941398A
Other languages
English (en)
French (fr)
Other versions
EP1192174A2 (de
Inventor
Gerald H Thomsen
Jeffrey Wrana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Research Foundation of the State University of New York
Original Assignee
HSC Research and Development LP
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HSC Research and Development LP, Research Foundation of the State University of New York filed Critical HSC Research and Development LP
Publication of EP1192174A2 publication Critical patent/EP1192174A2/de
Publication of EP1192174A4 publication Critical patent/EP1192174A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP00941398A 1999-06-11 2000-06-12 Antagonisten von bmp- und tgf-beta signalwegen Withdrawn EP1192174A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13896999P 1999-06-11 1999-06-11
US138969P 1999-06-11
PCT/US2000/016250 WO2000077168A2 (en) 1999-06-11 2000-06-12 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS

Publications (2)

Publication Number Publication Date
EP1192174A2 EP1192174A2 (de) 2002-04-03
EP1192174A4 true EP1192174A4 (de) 2002-08-28

Family

ID=22484504

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941398A Withdrawn EP1192174A4 (de) 1999-06-11 2000-06-12 Antagonisten von bmp- und tgf-beta signalwegen

Country Status (7)

Country Link
EP (1) EP1192174A4 (de)
JP (1) JP2003502064A (de)
CN (1) CN100379752C (de)
AU (1) AU782355B2 (de)
CA (1) CA2376675A1 (de)
IL (1) IL147005A0 (de)
WO (1) WO2000077168A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
WO2003030924A1 (en) * 2001-10-09 2003-04-17 Osteoscreen, Inc. Identification of specific modulators of bone formation
WO2005003167A1 (en) * 2003-07-01 2005-01-13 Vib Vzw Ubiquitinated tnf receptor 2 and its uses
US7901874B2 (en) * 2003-09-11 2011-03-08 Hubit Genomix, Inc. Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen
GB0526664D0 (en) * 2005-11-30 2006-02-08 Plasticell Ltd Method
KR100959050B1 (ko) 2006-03-01 2010-05-20 소프트맥스 인코퍼레이티드 분리된 신호를 생성하는 시스템 및 방법
EP2117583B1 (de) 2007-02-21 2013-05-22 Vib Vzw Kombinationstherapie mit TNF und alpha-Galactosylceramid
US20100183514A1 (en) * 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
US9403810B2 (en) * 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US9403833B2 (en) * 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
KR102360028B1 (ko) * 2014-12-26 2022-02-08 삼성전자주식회사 Smurf2의 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
CN110196326A (zh) * 2019-06-05 2019-09-03 武汉合研生物医药科技有限公司 一种TGFβR1(T204D)酶活性的快速检测方法及其应用
CN110592032B (zh) * 2019-10-14 2021-04-13 北京理工大学 泛素连接酶Smurf1突变体、编码基因及用途
US12098384B2 (en) 2021-01-21 2024-09-24 Cellid Co., Ltd. Adenoviral vector not including replication competent adenovirus, and use thereof
CN117721131A (zh) * 2023-12-19 2024-03-19 吉林大学 一种重组骨形态发生蛋白突变体的制备方法和应用
CN119386159B (zh) * 2024-12-31 2025-04-22 温州医科大学 一种mRNA-多肽复合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012962A1 (en) * 1995-10-04 1997-04-10 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741242B2 (en) * 1997-05-20 2001-11-29 Ludwig Institute For Cancer Research Smad2 phosphorylation and interaction with Smad4
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012962A1 (en) * 1995-10-04 1997-04-10 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto

Also Published As

Publication number Publication date
WO2000077168A2 (en) 2000-12-21
CN1409722A (zh) 2003-04-09
CN100379752C (zh) 2008-04-09
IL147005A0 (en) 2002-08-14
EP1192174A2 (de) 2002-04-03
AU5610700A (en) 2001-01-02
WO2000077168A3 (en) 2001-05-03
CA2376675A1 (en) 2000-12-21
AU782355B2 (en) 2005-07-21
JP2003502064A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
WO2000077168A3 (en) ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS
Coyle-Rink et al. Developmental expression of Wnt signaling factors in mouse brain
Edom‐Vovard et al. Signals regulating tendon formation during chick embryonic development
Borgs et al. Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus
Shirakabe et al. Roles of Meltrin β/ADAM19 in the processing of neuregulin
Allen et al. Hedgehog signaling regulates sebaceous gland development
Botchkarev et al. BMP signaling in the control of skin development and hair follicle growth
Grachtchouk et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype
Monteiro et al. Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins
Li et al. MEC-17 deficiency leads to reduced α-tubulin acetylation and impaired migration of cortical neurons
Lorda-Diez et al. Apoptosis during embryonic tissue remodeling is accompanied by cell senescence
Ito et al. Receptor‐regulated and inhibitory Smads are critical in regulating transforming growth factorβ–mediated Meckel's cartilage development
Monteiro et al. Real time monitoring of BMP Smads transcriptional activity during mouse development
Hosokawa et al. Epithelial‐specific requirement of FGFR2 signaling during tooth and palate development
Ito et al. Overexpression of Smad2 reveals its concerted action with Smad4 in regulating TGF-β-mediated epidermal homeostasis
Kablar et al. Skeletal muscle development in the mouse embryo.
WO2017132530A1 (en) Expansion and differentiation of inner ear supporting cells and methods of use thereof
Flügel‐Koch et al. Disruption of anterior segment development by TGF‐β1 overexpression in the eyes of transgenic mice
Zuscik et al. 5‐azacytidine alters TGF‐β and BMP signaling and induces maturation in articular chondrocytes
Liu et al. Transforming growth factor β2, but not β1 and β3, is critical for early rat lung branching
Muraoka et al. Mesenchymal expression of nuclear factor-κB inhibits epithelial growth and branching in the embryonic chick lung
US20070036769A9 (en) BMP pathway methods and compositions
Gos et al. Early neonatal and postweaning social emotional deprivation interferes with the maturation of serotonergic and tyrosine hydroxylase-immunoreactive afferent fiber systems in the rodent nucleus accumbens, hippocampus and amygdala
Alvarez et al. Unique and redundant roles of Smad3 in TGF‐β–mediated regulation of long bone development in organ culture
Alameda et al. Premature aging and cancer development in transgenic mice lacking functional CYLD

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020111

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020716

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 21/04 A, 7C 12N 15/00 B, 7C 07K 14/00 B, 7C 12N 9/00 B

17Q First examination report despatched

Effective date: 20050524

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100105